VEGFA and retinopathy of prematurity: Introduced by the RAINBOW trial, ranibizumab is a monoclonal antibody Fab fragment neutralizing VEGF-A that showed an advantage over laser therapy in managing ROP with a 24-week safety profile and fewer unfavorable ocular outcomes, such as high myopia [7,345].